Video

Yehuda Handelsman, MD: Organizing a Hybrid Cardiometabolic Meeting in 2021

Author(s):

The TMIOA Medical Director and Principal Investigator discusses the idea behind hosting a mixed in-person and virtual conference for this year's Heart in Diabetes.

The state of medical meetings are in flux in 2021. Previous successes in mitigating COVID-19 spread, afforded by early vaccine-induced immunity, provided organizers confidence to schedule in-person conference through this fall.

But with COVID-19 cases surging in past months, some meetings reverted to fully virtual capacity. Others sought to retain some semblance of in-person presentation.

In an interview with HCPLive at the conclusion of The Metabolic Institution of America (TMIOA) Heart in Diabetes sessions in New York, NY this weekend, meeting organizer Yehuda Handelsman, MD, discussed the intricacies that go into preparing a hybrid conference amid COVID-19.

Handelsman, the Medical Director and Principal Investigator for TMIOA, also discussed how this year’s iteration of cardiovascular and metabolic meetings—such as the European Society of Cardiology (ESC) and American Diabetes Association (ADA)—informed strategies for this year’s unique Heart in Diabetes sessions.

He stressed the meeting’s successes were based on TMIOA’s lesser following than such large-scale meetings, an appreciation for in-person sessions among a “Zoom fatigued” audience and, to an extent, luck. All presenters who initially committed to the in-person sessions did attend in New York; their virtual

“Virtual has its limits, even though it sounds easy,” Handelsman said. “We had several hundred people registered to come in person. I initially predicted that (registrants) would want no more than 150-200 people in attendance to get sort of (COVID-19 related) safety. We had just about 200 here.”

Related Videos
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
© 2024 MJH Life Sciences

All rights reserved.